SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-027867
Filing Date
2024-07-15
Accepted
2024-07-15 16:58:36
Documents
17
Period of Report
2024-07-10
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46329
2 ex3-1.htm EX-3.1 1479
3 ex3-1_001.jpg GRAPHIC 551639
4 ex3-1_002.jpg GRAPHIC 64963
  Complete submission text file 0001493152-24-027867.txt   1121062

Data Files

Seq Description Document Type Size
5 XBRL LABEL FILE cldi-20240710_lab.xml EX-101.LAB 36817
6 XBRL PRESENTATION FILE cldi-20240710_pre.xml EX-101.PRE 25307
7 XBRL SCHEMA FILE cldi-20240710.xsd EX-101.SCH 3813
8 XBRL DEFINITION FILE cldi-20240710_def.xml EX-101.DEF 26683
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6083
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 241117895
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)